About Us

Founded in 2005, C3 Jian, Inc ("C3") is a clinical-stage biotechnology company based in Los Angeles, California. The Company’s technologies were pioneered in the laboratories of Dr. Wenyuan Shi, Chairman of Oral Biology at the University of California Los Angeles (UCLA) School of Dentistry, as well as Professor of Microbiology at the UCLA School of Medicine. We are currently developing therapeutic and diagnostic products to improve oral health.

History

A brief overview of the history of C3 can be found below. C3 has worked closely with UCLA on development of its novel technologies.

Our proprietary platform technology uses signal transduction, or the signaling devices that cells use to communicate with one another. We utilize these signaling molecules to design specifically targeted therapeutic and diagnostic product candidates that can attach directly to the cell (bacteria) of interest. C3 licensed its platform technology from UCLA on a worldwide, exclusive basis.

The Company refers to its targeted compounds as STAMPS, or Specifically Targeted Antimicrobial Peptides. Our lead anti-infective STAMPS are targeted against bacterial and fungal infections, specifically those occurring at mucosal surfaces where clear benefits are associated with retaining beneficial bacteria that conventional antibiotics would destroy.

2004
  • UCLA researchers successfully develop first prototype Specifically-Targeted Antimicrobial Peptide, or STAMP

2005
  • UCLA researchers develop lead biomineralization modulating peptide
  • C3 Jian, Inc. is established to develop and commercialize UCLA inventions
  • UCLA receives research funding from Washington Dental Services (Delta Dental of Washington)
  • Co-Founder Dr. Maxwell Anderson is named C3’s first President & CEO

2006
  • UCLA researchers develop lead STAMP against S. mutans
  • Initial funding of C3 is secured through the dental insurance company Delta Dental of Wisconsin

2007
  • C3 opens its first R&D laboratories in Inglewood, CA
  • Additional investments are received from insurance companies Delta Dental of Virginia and Delta Dental of Michigan (representing several states)

2008
  • C3 advances R&D on STAMPs and biomineralization modulating peptides
  • Lead compound/formulations for calcification of teeth are developed; animal safety testing leads to discovery of hair and nail growth properties

2009
  • C3 Inglewood Peptide Synthesis Center opened
  • “Chairside” prototype peptide-based S. mutans diagnostic constructed
  • C3 tests its lead compound, Sm STAMPS, against dental caries in human testing under IRB (Institutional Review Board) approval
  • Company closes $15 million financing round; total equity capital raised to date = $27 million

2010
  • C3 establishes Wholly owned Foreign Entity (WOFE) in Chengdu, China; first employees hired
  • In November, Todd R. Patrick named President and CEO. Patrick is first “non-Founder” CEO

2011
  • Company undertakes non-clinical studies related to Sm STAMP in preparation for filing an IND application with the FDA for human studies
  • C3 WOFE in China opens first office/laboratory facility
  • C3 completes formulation work for STAMP peptide-based hair growth product
  • Laura A. Navalta hired as C3 Vice President, Clinical Operations